IBT — International Biotechnology Trust Income Statement
0.000.00%
Last trade - 00:00FinancialsBalancedSmall Cap
- £310.10m
- £324.72m
- £6.07m
Annual income statement for International Biotechnology Trust, fiscal year end - August 31st, GBP millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | 2025 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 32.1 | -18 | 12.1 | 44.5 | 6.07 |
| Cost of Revenue | |||||
| Gross Profit | 29.1 | -21.1 | 8.49 | 40.1 | -0.175 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 4.05 | 4.36 | 5.13 | 5.53 | 7.21 |
| Operating Profit | 28 | -22.3 | 6.93 | 39 | -1.14 |
| Net Income Before Taxes | 28 | -22.3 | 6.93 | 39 | -1.14 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 27.9 | -22.5 | 6.81 | 38.9 | -1.17 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 27.9 | -22.5 | 6.81 | 38.9 | -1.17 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 27.9 | -22.5 | 6.81 | 38.9 | -1.17 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.689 | -0.547 | 0.168 | 1.02 | -0.033 |
| Dividends per Share |